MerTK cleavage limits proresolving mediator biosynthesis and exacerbates tissue inflammation

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 23, 2016, Pages 6526-6531

  Cai, Bishuang ^a,b   Thorp, Edward B ^c   Doran, Amanda C ^a,b   Subramanian, Manikandan ^a,b   Sansbury, Brian E ^d   Lin, Chyuan Sheng ^a,b   Spite, Matthew ^d   Fredman, Gabrielle ^e   Tabas, Ira ^a,b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NewYork Presbyterian Hospital   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e ALBANY MEDICAL COLLEGE   (United States)

Author keywords

5 lipoxygenase; Efferocytosis; Inflammation resolution; Macrophages; MerTK

Indexed keywords

ADAM PROTEIN; ARACHIDONATE 5 LIPOXYGENASE; MER PROTO ONCOGENE TYROSINE KINASE; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; ADAM17 PROTEIN, MOUSE; AUTACOID; MERTK PROTEIN, MOUSE; ONCOPROTEIN; PROTEIN TYROSINE KINASE; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOSYNTHESIS; CONTROLLED STUDY; INFLAMMATION; LUNG INJURY; MACROPHAGE; MEDIATOR; MOUSE; NONHUMAN; PERITONITIS; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DOMAIN; REPERFUSION INJURY; ANIMAL; C57BL MOUSE; DEFICIENCY; DISEASE MODEL; FEMALE; GENETICS; HUMAN; KNOCKOUT MOUSE; MALE; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

ADAM17 PROTEIN; ANIMALS; ARACHIDONATE 5-LIPOXYGENASE; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; LUNG INJURY; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PERITONITIS; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; REPERFUSION INJURY; SIGNAL TRANSDUCTION;

EID: 84973397896     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1524292113     Document Type: Article

References (59)

1. Serhan CN (2014) Pro-resolving lipid mediators are leads for resolution physiology. Nature 510(7503):92-101.
2. Medzhitov R (2010) Inflammation 2010: New adventures of an old flame. Cell 140(6): 771-776.
3. Nathan C, Ding A (2010) Nonresolving inflammation. Cell 140(6):871-882.
4. Tabas I, Glass CK (2013) Anti-inflammatory therapy in chronic disease: Challenges and opportunities. Science 339(6116):166-172.
5. Viola J, Soehnlein O (2015) Atherosclerosis-A matter of unresolved inflammation. Semin Immunol 27(3):184-193.
6. Perretti M, D'Acquisto F (2009) Annexin A1 and glucocorticoids as effectors of the resolution of inflammation. Nat Rev Immunol 9(1):62-70.
7. Wallace JL, Ianaro A, Flannigan KL, Cirino G (2015) Gaseous mediators in resolution of inflammation. Semin Immunol 27(3):227-233.
8. Buckley CD, Gilroy DW, Serhan CN (2014) Proresolving lipid mediators and mechanisms in the resolution of acute inflammation. Immunity 40(3):315-327.
9. Serhan CN, et al. (2002) Resolvins: A family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med 196(8):1025-1037.
10. Serhan CN, Hamberg M, Samuelsson B (1984) Lipoxins: Novel series of biologically active compounds formed from arachidonic acid in human leukocytes. Proc Natl Acad Sci USA 81(17):5335-5339.
11. Fredman G, et al. (2014) Resolvin D1 limits 5-lipoxygenase nuclear localization and leukotriene B4 synthesis by inhibiting a calcium-activated kinase pathway. Proc Natl Acad Sci USA 111(40):14530-14535.
12. Norling LV, Dalli J, Flower RJ, Serhan CN, Perretti M (2012) Resolvin D1 limits polymorphonuclear leukocyte recruitment to inflammatory loci: Receptor-dependent actions. Arterioscler Thromb Vasc Biol 32(8):1970-1978.
13. Lemke G, Burstyn-Cohen T (2010) TAM receptors and the clearance of apoptotic cells. Ann N Y Acad Sci 1209:23-29.
14. Lemke G (2013) Biology of the TAM receptors. Cold Spring Harb Perspect Biol 5(11): a009076.
15. Lee YJ, et al. (2012) InhibitingMer receptor tyrosine kinase suppresses STAT1, SOCS1/3, and NF-?B activation and enhances inflammatory responses in lipopolysaccharide-induced acute lung injury. J Leukoc Biol 91(6):921-932.
16. Choi JY, et al. (2013) Upregulation of Mer receptor tyrosine kinase signaling attenuated lipopolysaccharide-induced lung inflammation. J Pharmacol Exp Ther 344(2): 447-458.
17. Cohen PL, et al. (2002) Delayed apoptotic cell clearance and lupus-like autoimmunity in mice lacking the c-mer membrane tyrosine kinase. J Exp Med 196(1):135-140.
18. Thorp E, Cui D, Schrijvers DM, Kuriakose G, Tabas I (2008) Mertk receptor mutation reduces efferocytosis efficiency and promotes apoptotic cell accumulation and plaque necrosis in atherosclerotic lesions of apoe-/-mice. Arterioscler Thromb Vasc Biol 28(8): 1421-1428.
19. Ait-Oufella H, et al. (2008) Defective mer receptor tyrosine kinase signaling in bone marrow cells promotes apoptotic cell accumulation and accelerates atherosclerosis. Arterioscler Thromb Vasc Biol 28(8):1429-1431.
20. Choi JY, et al. (2015) Mer signaling increases the abundance of the transcription factor LXR to promote the resolution of acute sterile inflammation. Sci Signal 8(365): ra21.
21. Sather S, et al. (2007) A soluble form of the Mer receptor tyrosine kinase inhibits macrophage clearance of apoptotic cells and platelet aggregation. Blood 109(3): 1026-1033.
22. Thorp E, et al. (2011) Shedding of the Mer tyrosine kinase receptor is mediated by ADAM17 protein through a pathway involving reactive oxygen species, protein kinase Cδ, and p38 mitogen-activated protein kinase (MAPK). J Biol Chem 286(38): 33335-33344.
23. Wu J, et al. (2011) Increased plasma levels of the soluble Mer tyrosine kinase receptor in systemic lupus erythematosus relate to disease activity and nephritis. Arthritis Res Ther 13(2):R62.
24. Zizzo G, Guerrieri J, Dittman LM, Merrill JT, Cohen PL (2013) Circulating levels of soluble MER in lupus reflect M2c activation of monocytes/macrophages, autoantibody specificities and disease activity. Arthritis Res Ther 15(6):R212.
25. Garbin U, et al. (2013) Expansion of necrotic core and shedding of Mertk receptor in human carotid plaques: A role for oxidized polyunsaturated fatty acids? Cardiovasc Res 97(1):125-133.
26. Schwab JM, Chiang N, Arita M, Serhan CN (2007) Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 447(7146):869-874.
27. Dalli J, Serhan CN (2012) Specific lipid mediator signatures of human phagocytes: Microparticles stimulate macrophage efferocytosis and pro-resolving mediators. Blood 120(15):e60-e72.
28. Bannenberg GL, et al. (2005) Molecular circuits of resolution: Formation and actions of resolvins and protectins. J Immunol 174(7):4345-4355.
29. Serhan CN, Chiang N, Van Dyke TE (2008) Resolving inflammation: Dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 8(5):349-361.
30. Zagórska A, Través PG, Lew ED, Dransfield I, Lemke G (2014) Diversification of TAM receptor tyrosine kinase function. Nat Immunol 15(10):920-928.
31. Yassin MM, Harkin DW, Barros D'Sa AA, Halliday MI, Rowlands BJ (2002) Lower limb ischemia-reperfusion injury triggers a systemic inflammatory response and multiple organ dysfunction. World J Surg 26(1):115-121.
32. Shinohara M, et al. (2014) Cell-cell interactions and bronchoconstrictor eicosanoid reduction with inhaled carbon monoxide and resolvin D1. Am J Physiol Lung Cell Mol Physiol 307(10):L746-L757.
33. McCabe AJ, Dowhy M, Holm BA, Glick PL (2001) Myeloperoxidase activity as a lung injury marker in the lamb model of congenital diaphragmatic hernia. J Pediatr Surg 36(2):334-337.
34. Matute-Bello G, et al.; Acute Lung Injury in Animals Study Group (2011) An official American Thoracic Society workshop report: Features and measurements of experimental acute lung injury in animals. Am J Respir Cell Mol Biol 44(5):725-738.
35. Freire-de-Lima CG, et al. (2006) Apoptotic cells, through transforming growth factorbeta, coordinately induce anti-inflammatory and suppress pro-inflammatory eicosanoid and NO synthesis in murine macrophages. J Biol Chem 281(50):38376-38384.
36. Rådmark O, Samuelsson B (2005) Regulation of 5-lipoxygenase enzyme activity. Biochem Biophys Res Commun 338(1):102-110.
37. Werz O, Szellas D, Steinhilber D, Rådmark O (2002) Arachidonic acid promotes phosphorylation of 5-lipoxygenase at Ser-271 by MAPK-activated protein kinase 2 (MK2). J Biol Chem 277(17):14793-14800.
38. Rothlin CV, Carrera-Silva EA, Bosurgi L, Ghosh S (2015) TAM receptor signaling in immune homeostasis. Annu Rev Immunol 33:355-391.
39. Scott RS, et al. (2001) Phagocytosis and clearance of apoptotic cells is mediated by MER. Nature 411(6834):207-211.
40. Camenisch TD, Koller BH, Earp HS, Matsushima GK (1999) A novel receptor tyrosine kinase, Mer, inhibits TNF-alpha production and lipopolysaccharide-induced endotoxic shock. J Immunol 162(6):3498-3503.
41. Tibrewal N, et al. (2008) Autophosphorylation docking site Tyr-867 in Mer receptor tyrosine kinase allows for dissociation of multiple signaling pathways for phagocytosis of apoptotic cells and down-modulation of lipopolysaccharide-inducible NF-kappaB transcriptional activation. J Biol Chem 283(6):3618-3627.
42. Rothlin CV, Ghosh S, Zuniga EI, Oldstone MB, Lemke G (2007) TAM receptors are pleiotropic inhibitors of the innate immune response. Cell 131(6):1124-1136.
43. Eken C, et al. (2010) Ectosomes released by polymorphonuclear neutrophils induce a MerTK-dependent anti-inflammatory pathway in macrophages. J Biol Chem 285(51): 39914-39921.
44. Cumpelik A, Ankli B, Zecher D, Schifferli JA (2015) Neutrophil microvesicles resolve gout by inhibiting C5a-mediated priming of the inflammasome. Ann Rheum Dis.
45. Wallet MA, et al. (2008) MerTK is required for apoptotic cell-induced T cell tolerance. J Exp Med 205(1):219-232.
46. McColl A, et al. (2009) Glucocorticoids induce protein S-dependent phagocytosis of apoptotic neutrophils by human macrophages. J Immunol 183(3):2167-2175.
47. A-Gonzalez N, et al. (2009) Apoptotic cells promote their own clearance and immune tolerance through activation of the nuclear receptor LXR. Immunity 31(2):245-258.
48. Heo KS, et al. (2014) ERK5 activation in macrophages promotes efferocytosis and inhibits atherosclerosis. Circulation 130(2):180-191.
49. Beil WJ, Meinardus-Hager G, Neugebauer DC, Sorg C (1992) Differences in the onset of the inflammatory response to cutaneous leishmaniasis in resistant and susceptible mice. J Leukoc Biol 52(2):135-142.
50. Lagrota-Candido J, et al. (2010) Characteristic pattern of skeletal muscle remodelling in different mouse strains. Int J Exp Pathol 91(6):522-529.
51. Freire MO, Van Dyke TE (2013) Natural resolution of inflammation. Periodontol 2000 63(1):149-164.
52. Bell JH, Herrera AH, Li Y, Walcheck B (2007) Role of ADAM17 in the ectodomain shedding of TNF-alpha and its receptors by neutrophils and macrophages. J Leukoc Biol 82(1):173-176.
53. Tsou WI, et al. (2014) Receptor tyrosine kinases, TYRO3, AXL, and MER, demonstrate distinct patterns and complex regulation of ligand-induced activation. J Biol Chem 289(37):25750-25763.
54. Warming S, Costantino N, Court DL, Jenkins NA, Copeland NG (2005) Simple and highly efficient BAC recombineering using galK selection. Nucleic Acids Res 33(4):e36.
55. Arnardottir HH, Dalli J, Colas RA, Shinohara M, Serhan CN (2014) Aging delays resolution of acute inflammation in mice: reprogramming the host response with novel nano-proresolving medicines. J Immunol 193(8):4235-4244.
56. Flamand N, Luo M, Peters-Golden M, Brock TG (2009) Phosphorylation of serine 271 on 5-lipoxygenase and its role in nuclear export. J Biol Chem 284(1):306-313.
57. Markoutsa S, et al. (2014) Analysis of 5-lipoxygenase phosphorylation on molecular level by MALDI-MS. FEBS J 281(8):1931-1947.
58. Rådmark O, Werz O, Steinhilber D, Samuelsson B (2007) 5-Lipoxygenase: Regulation of expression and enzyme activity. Trends Biochem Sci 32(7):332-341.
59. Colas RA, Shinohara M, Dalli J, Chiang N, Serhan CN (2014) Identification and signature profiles for pro-resolving and inflammatory lipid mediators in human tissue. Am J Physiol Cell Physiol 307(1):C39-C54.